I am a
Home I AM A Search Login

Papers of the Week

Papers: 5 Mar 2022 - 11 Mar 2022

Pharmacology/Drug Development

2022 Feb 28

J Allergy Clin Immunol

Mechanistic Insights into the Anti-Pruritic Effects of Lebrikizumab, an Anti-IL-13 Monoclonal Antibody.


Miron Y, Miller PE, Hughes C, Indersmitten T, Lerner EA, Cevikbas F
J Allergy Clin Immunol. 2022 Feb 28.
PMID: 35240144.


Atopic dermatitis (AD) is a chronic, inflammatory skin disease with persistent and severe itch among its hallmark features. Significant increases in type 2 cytokines (i.e., IL-4, IL-13, IL-31) have been documented in acute AD lesions and lead to multi-faceted downstream effects, including inflammation, epidermal barrier dysfunction, and itch.